Shanghai Haohai Biological Technology Bilanço Sağlığı
Finansal Sağlık kriter kontrolleri 5/6
Shanghai Haohai Biological Technology şirketinin toplam hissedar öz sermayesi CN¥6.0B ve toplam borcu CN¥423.7M olup, bu da borç-öz sermaye oranını 7% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla CN¥7.2B ve CN¥1.2B dir. Shanghai Haohai Biological Technology 'in FAVÖK'ü CN¥404.8M faiz karşılama oranı -6.4 dur. Şirketin CN¥2.7B tutarında nakit ve kısa vadeli yatırımları bulunmaktadır.
Anahtar bilgiler
7.0%
Borç/özkaynak oranı
CN¥423.70m
Borç
| Faiz karşılama oranı | -6.4x |
| Nakit | CN¥2.69b |
| Eşitlik | CN¥6.03b |
| Toplam yükümlülükler | CN¥1.21b |
| Toplam varlıklar | CN¥7.25b |
Son finansal sağlık güncellemeleri
We Think Shanghai Haohai Biological Technology (HKG:6826) Can Manage Its Debt With Ease
Jul 25
Shanghai Haohai Biological Technology (HKG:6826) Seems To Use Debt Rather Sparingly
Apr 17Is Shanghai Haohai Biological Technology (HKG:6826) Using Too Much Debt?
Nov 14Shanghai Haohai Biological Technology (HKG:6826) Has A Pretty Healthy Balance Sheet
Jul 28We Think Shanghai Haohai Biological Technology (HKG:6826) Can Stay On Top Of Its Debt
Mar 09These 4 Measures Indicate That Shanghai Haohai Biological Technology (HKG:6826) Is Using Debt Reasonably Well
Nov 25Recent updates
We Think Shanghai Haohai Biological Technology (HKG:6826) Can Manage Its Debt With Ease
Jul 25Why We Think Shanghai Haohai Biological Technology Co., Ltd.'s (HKG:6826) CEO Compensation Is Not Excessive At All
May 22Shanghai Haohai Biological Technology (HKG:6826) Seems To Use Debt Rather Sparingly
Apr 17Are Shanghai Haohai Biological Technology Co., Ltd. (HKG:6826) Investors Paying Above The Intrinsic Value?
Feb 12Is Shanghai Haohai Biological Technology (HKG:6826) Using Too Much Debt?
Nov 14Shanghai Haohai Biological Technology (HKG:6826) Has A Pretty Healthy Balance Sheet
Jul 28We Think Shanghai Haohai Biological Technology (HKG:6826) Can Stay On Top Of Its Debt
Mar 09These 4 Measures Indicate That Shanghai Haohai Biological Technology (HKG:6826) Is Using Debt Reasonably Well
Nov 25Shanghai Haohai Biological Technology (HKG:6826) Has A Pretty Healthy Balance Sheet
Jul 30Shanghai Haohai Biological Technology Co., Ltd.'s (HKG:6826) Intrinsic Value Is Potentially 96% Above Its Share Price
May 08Is Shanghai Haohai Biological Technology (HKG:6826) Using Too Much Debt?
Apr 19Analyst Forecasts Just Became More Bearish On Shanghai Haohai Biological Technology Co., Ltd. (HKG:6826)
Mar 04Shanghai Haohai Biological Technology Co., Ltd. Just Missed Earnings - But Analysts Have Updated Their Models
Mar 03Is Shanghai Haohai Biological Technology (HKG:6826) A Risky Investment?
Jan 10Shanghai Haohai Biological Technology (HKG:6826) Seems To Use Debt Rather Sparingly
Oct 08Here's Why Shanghai Haohai Biological Technology (HKG:6826) Can Manage Its Debt Responsibly
Jul 07Analysts Have Just Cut Their Shanghai Haohai Biological Technology Co., Ltd. (HKG:6826) Revenue Estimates By 14%
May 27These 4 Measures Indicate That Shanghai Haohai Biological Technology (HKG:6826) Is Using Debt Reasonably Well
Apr 04Investors Who Bought Shanghai Haohai Biological Technology (HKG:6826) Shares A Year Ago Are Now Up 58%
Mar 16Finansal Durum Analizi
Kısa Vadeli Yükümlülükler: 6826 'nin kısa vadeli varlıkları ( CN¥3.7B ) kısa vadeli yükümlülüklerini ( CN¥861.5M ) aşıyor.
Uzun Vadeli Yükümlülükler: 6826 şirketinin kısa vadeli varlıkları ( CN¥3.7B ) uzun vadeli yükümlülüklerini ( CN¥350.6M ) aşmaktadır.
Borç-Özkaynak Tarihçesi ve Analizi
Borç Seviyesi: 6826 şirketinin toplam borcundan daha fazla nakiti var.
Borcun Azaltılması: 6826 şirketinin borç/öz sermaye oranı son 5 yılda 0.7% seviyesinden 7% seviyesine yükseldi.
Borç Kapsamı: 6826 'nin borcu işletme nakit akışı ( 159% ) tarafından iyi bir şekilde karşılanmaktadır.
Faiz Kapsamı: 6826 ödediğinden daha fazla faiz kazandırıyor, dolayısıyla faiz ödemelerinin karşılanması bir sorun teşkil etmiyor.